Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 4.91B |
| Revenue (ttm) | 115.91M |
| Net Income (ttm) | -155.47M |
| Shares Out | 138.97M |
| EPS (ttm) | -1.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $34.99 |
| Previous Close | $36.60 |
| Change ($) | -1.61 |
| Change (%) | -4.40% |
| Day's Open | 36.53 |
| Day's Range | 34.86 - 37.51 |
| Day's Volume | 1,747,590 |
| 52-Week Range | 33.53 - 71.25 |
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 29.27% and 34.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...
Adaptive Biotechnologies (NASDAQ:ADPT) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...
Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste...
Viking Global leader Andreas Holversen disclosed a stake in Orion Acquisition Corp. (NASDAQ:OHPAU) earlier this month, joining a growing number of investors who are seeing value opportunities in special...
SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste...
Adaptive Biotech T cell test receives FDA approval for emergency use
Adaptive Biotech's T cell test will help detect whether you've had Covid-19 before or not. The test just received FDA approval for emergency use.
The shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) are sinking even lower today, following a price-target cut to $60 from $68 from Guggenheim.
The FDA issued the Emergency Use Authorization (EUA) to Adaptive Biotechnologies Corp's (NASDAQ: ADPT) T-Detect COVID-19 Test on Friday. It will be used to determine whether an individual had been infec...
First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19
2020 was a year that will be hard to forget. The headlines were dominated by the pandemic and its social and economic aftermath, but there were also wildfires, violent social and racial unrest, the U.S....
SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...
Seattle-based Adaptive Biotechnologies, which sequences the human immune system to diagnose and treat disease, posted revenue of $30.
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 94.12% year over year to ($0.33), whic...
SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...
Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection. T-Detect is currently under review by the FDA for Emergency Use Aut...
SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA)
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Multi-year, pan-portfolio deal extends Adaptive's proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology
During GuruFocus' annual model portfolio rebalance for 2021, the new stocks added to the Most Weighted Model Portfolio were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), AerCap Holdings NV (NYSE:AER), A...
SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...
Investors need to pay close attention to Adaptive Biotechnologies (ADPT) stock based on the movements in the options market lately.
According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adap...
MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with clonoSEQ imp...
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global, disclosed this week that his firm's top sells during the third quarter were in Amazon.com Inc. (NASDAQ:AMZN), Comcast Corp. (N...
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Adaptive Biotechnologies says it's proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added...
– Findings support upcoming launch of T-Detect ™ COVID , first T- cell test for novel coronavirus – Data support mounting evidence that measuring T- cell s is necessary to fully characteriz e immune res...
Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q3 2020 Results - Earnings Call Transcript
Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 145.45% over the past year to ($0.27),...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotech CEO says it's working to develop the best antibody treatment for Covid-19
Adaptive biotechnologies CEO Chad Robins says the company is working night and day to develop an effective antibody Covid-19 treatment. He says the company won't be first to provide antibody treatments,...
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease i... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| CEO Chad Robins | Employees 622 |
| Stock Exchange NASDAQ | Ticker Symbol ADPT |
Financial Performance
In 2020, ADPT's revenue was $98.38 million, an increase of 15.65% compared to the previous year's $85.07 million. Losses were -$146.23 million, 113.1% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 62.00, which is an increase of 77.19% from the latest price.